The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 17, 2018

Filed:

May. 27, 2015
Applicant:

Academia Sinica, Taipei, TW;

Inventors:

Chi-Huey Wong, Rancho Santa Fe, CA (US);

Chung-Yi Wu, New Taipei, TW;

Che Ma, Taipei, TW;

Assignee:

ACADEMIA SINICA, Taipei, TW;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C12P 19/14 (2006.01); A61K 39/395 (2006.01); A61K 39/42 (2006.01); A61K 45/06 (2006.01); C07K 16/10 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); C12N 9/24 (2006.01); C07K 16/18 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12P 19/14 (2013.01); A61K 39/3955 (2013.01); A61K 39/42 (2013.01); A61K 45/06 (2013.01); C07K 16/00 (2013.01); C07K 16/1018 (2013.01); C07K 16/18 (2013.01); C07K 16/241 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); C12N 9/24 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/41 (2013.01); C07K 2317/72 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/92 (2013.01); C12Y 302/01 (2013.01); C12Y 302/01051 (2013.01);
Abstract

The present disclosure relates to glycoproteins, particularly monoclonal antibodies, comprising a glycoengineered Fc region, wherein said Fc region comprises an optimized N-glycan having the structure of Sia(α2-6)GalGlcNAcManGlcNAc. The glycoengineered Fc region binds FcγRIIA or FcγRIIIA with a greater affinity, relative to comparable monoclonal antibodies comprising the wild-type Fc region. The monoclonal antibodies of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, autoimmune, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.


Find Patent Forward Citations

Loading…